Trial Profile
A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs KUR-111 (Primary)
- Indications Fracture
- Focus Therapeutic Use
- 09 Oct 2015 Results from this trial presented at the 2015 Orthopaedic Trauma Association Annual Meeting, according to a Kuros Biotechnology media release.
- 09 Oct 2015 Results published in a Kuros Biosurgery media release.
- 29 Jun 2012 New source identified and integrated: European Clinical Trials Database record EudraCT2006-003688-30.